{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:13:00Z","timestamp":1782450780285,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Cannabis use may introduce risks and\/or benefits among people living with cancer, depending on product type, composition, and nature of its use. Patient knowledge of tetrahydrocannabinol (THC) or cannabidiol (CBD) concentration could provide information for providers about cannabis use during and after treatment that may aide in risk and benefit assessments. This study aimed to examine knowledge of THC or CBD concentration among patients living with cancer who consume cannabis, and factors associated with knowledge of cannabinoid concentrations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>People living with cancer who consumed cannabis since their diagnosis (<jats:italic>n<\/jats:italic>\u2009=\u2009343) completed an anonymous, mixed-mode survey. Questions assessed usual mode of delivery (MOD), knowledge of THC\/CBD concentration, and how source of acquisition, current cannabis use, and source of instruction are associated with knowledge of THC\/CBD concentration. Chi-square and separate binary logistic regression analyses were examined and weighted to reflect the Roswell Park patient population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Less than 20% of people living with cancer had knowledge of THC and CBD concentration for the cannabis products they consumed across all MOD (smoking- combustible products, vaping- vaporized products (e-cigarettes), edibles-eating or drinking it, and oral- taking by mouth (pills)). Source of acquisition (smoking-AOR:4.6, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01, vaping-AOR:5.8, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00, edibles-AOR:2.6, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.04), current cannabis use (edibles-AOR:5.4, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01, vaping-AOR: 11.2, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00, and oral-AOR:9.3, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00), and source of instruction (vaping only AOR:4.2, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) were found to be variables associated with higher knowledge of THC concentration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Self-reported knowledge of THC and CBD concentration statistically differed according to MOD, source of acquisition, source of instruction, and current cannabis use.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-024-08374-w","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T19:02:12Z","timestamp":1709665332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Self-reported knowledge of tetrahydrocannabinol and cannabidiol concentration in cannabis products among cancer patients and survivors"],"prefix":"10.1007","volume":"32","author":[{"given":"Michelle","family":"Goulette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas J.","family":"Schlienz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Rivard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Ashare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej L.","family":"Goniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maansi","family":"Bansal-Travers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"8374_CR1","unstructured":"Where marijuana is legal in the United States. https:\/\/mjbizdaily.com\/map-of-us-marijuana-legalization-by-state\/ (2022). Accessed August 26 2022"},{"issue":"3","key":"8374_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/can.2020.0092","volume":"7","author":"D Hammond","year":"2022","unstructured":"Hammond D, Goodman S (2022) Knowledge of tetrahydrocannabinol and cannabidiol levels among cannabis consumers in the United States and Canada. Cannabis Cannabinoid Res 7(3):345\u2013354","journal-title":"Cannabis Cannabinoid Res"},{"key":"8374_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.drugpo.2018.03.031","volume":"57","author":"JP Caulkins","year":"2018","unstructured":"Caulkins JP, Bao Y, Davenport S, Fahli I, Guo Y, Kinnard K et al (2018) Big data on a big new market: Insights from Washington State\u2019s legal cannabis market. Int J Drug Policy 57:86\u201394","journal-title":"Int J Drug Policy"},{"issue":"1","key":"8374_CR4","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1038\/s41598-018-22755-2","volume":"8","author":"N Jikomes","year":"2018","unstructured":"Jikomes N, Zoorob M (2018) The cannabinoid content of legal cannabis in Washington state varies systematically across testing facilities and popular consumer products. Sci Rep 8(1):4519","journal-title":"Sci Rep"},{"issue":"4","key":"8374_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCO.0000000000000523","volume":"31","author":"D Lossignol","year":"2019","unstructured":"Lossignol D (2019) Cannabinoids: a new approach for pain control? Curr Opin Oncol 31(4):275\u2013279","journal-title":"Curr Opin Oncol"},{"key":"8374_CR6","doi-asserted-by":"crossref","unstructured":"Pennypacker SD, Cunnane K, Cash MC, Romero-Sandoval EA (2022) Potency and therapeutic THC and CBD ratios: US cannabis markets overshoot. Front Pharmacol 13:921493","DOI":"10.3389\/fphar.2022.921493"},{"key":"8374_CR7","unstructured":"National Academies of Sciences, Engineering, and Medicine (2017) The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. National Academies Press (US), Washington, DC"},{"key":"8374_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jpba.2017.06.003","volume":"147","author":"C Citti","year":"2018","unstructured":"Citti C, Braghiroli D, Vandelli MA, Cannazza G (2018) Pharmaceutical and biomedical analysis of cannabinoids: A critical review. J Pharm Biomed Anal 147:565\u2013579","journal-title":"J Pharm Biomed Anal"},{"key":"8374_CR9","doi-asserted-by":"crossref","unstructured":"Lawn W, Trinci K, Mokrysz C, Borissova A, Ofori S, Petrilli K, Curran HV (2023) The acute effects of cannabis with and without cannabidiol in adults and adolescents: a randomised, double\u2010blind, placebo\u2010controlled, crossover experiment. Addiction 118(7):1282\u20131294","DOI":"10.1111\/add.16154"},{"issue":"5","key":"8374_CR10","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/add.15253","volume":"116","author":"TP Freeman","year":"2021","unstructured":"Freeman TP, Craft S, Wilson J, Stylianou S, ElSohly M, Di Forti M et al (2021) Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction 116(5):1000\u20131010","journal-title":"Addiction"},{"issue":"3","key":"8374_CR11","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","volume":"2","author":"F Leweke","year":"2012","unstructured":"Leweke F, Piomelli D, Pahlisch F, Muhl D, Gerth C, Hoyer C et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2(3):e94-e","journal-title":"Transl Psychiatry."},{"issue":"1\u20133","key":"8374_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.schres.2015.01.033","volume":"162","author":"TA Iseger","year":"2015","unstructured":"Iseger TA, Bossong MG (2015) A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 162(1\u20133):153\u2013161","journal-title":"Schizophr Res"},{"issue":"21","key":"8374_CR13","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R et al (2017) Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 376(21):2011\u20132020","journal-title":"N Engl J Med"},{"issue":"1","key":"8374_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00406-019-00983-5","volume":"269","author":"S Chandra","year":"2019","unstructured":"Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA (2019) New trends in cannabis potency in USA and Europe during the last decade (2008\u20132017). Eur Arch Psychiatry Clin Neurosci 269(1):5\u201315","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"8374_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/dar.13069","volume":"39","author":"S Mahamad","year":"2020","unstructured":"Mahamad S, Wadsworth E, Rynard V, Goodman S, Hammond D (2020) Availability, retail price and potency of legal and illegal cannabis in Canada after recreational cannabis legalisation. Drug Alcohol Rev 39(4):337\u2013346","journal-title":"Drug Alcohol Rev"},{"issue":"9","key":"8374_CR16","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1007\/s11606-018-4480-0","volume":"33","author":"S Steigerwald","year":"2018","unstructured":"Steigerwald S, Wong PO, Khorasani A, Keyhani S (2018) The form and content of cannabis products in the United States. J Gen Intern Med 33(9):1426\u20131428","journal-title":"J Gen Intern Med"},{"issue":"1","key":"8374_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amepre.2015.05.027","volume":"50","author":"GL Schauer","year":"2016","unstructured":"Schauer GL, King BA, Bunnell RE, Promoff G, McAfee TA (2016) Toking, vaping, and eating for health or fun: marijuana use patterns in adults, US, 2014. Am J Prev Med 50(1):1\u20138","journal-title":"Am J Prev Med"},{"issue":"1","key":"8374_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-016-0119-9","volume":"13","author":"S Shiplo","year":"2016","unstructured":"Shiplo S, Asbridge M, Leatherdale ST, Hammond D (2016) Medical cannabis use in Canada: vapourization and modes of delivery. Harm Reduct J 13(1):1\u201310","journal-title":"Harm Reduct J"},{"key":"8374_CR19","doi-asserted-by":"publisher","first-page":"109159","DOI":"10.1016\/j.drugalcdep.2021.109159","volume":"229","author":"DS Hasin","year":"2021","unstructured":"Hasin DS, Borodovsky J, Shmulewitz D, Walsh C, Livne O, Struble CA et al (2021) Use of highly-potent cannabis concentrate products: More common in US states with recreational or medical cannabis laws. Drug Alcohol Depend 229:109159","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"8374_CR20","doi-asserted-by":"publisher","first-page":"e0230167","DOI":"10.1371\/journal.pone.0230167","volume":"15","author":"MC Cash","year":"2020","unstructured":"Cash MC, Cunnane K, Fan C, Romero-Sandoval EA (2020) Mapping cannabis potency in medical and recreational programs in the United States. PLoS ONE 15(3):e0230167","journal-title":"PLoS ONE"},{"issue":"2","key":"8374_CR21","doi-asserted-by":"publisher","first-page":"e2254752","DOI":"10.1001\/jamanetworkopen.2022.54752","volume":"6","author":"CA Zamarripa","year":"2023","unstructured":"Zamarripa CA, Spindle TR, Surujunarain R, Weerts EM, Bansal S, Unadkat JD et al (2023) (2023) Assessment of Orally Administered \u03949-Tetrahydrocannabinol When Coadministered With Cannabidiol on \u03949-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial. JAMA Netw Open 6(2):e2254752-e","journal-title":"JAMA Netw Open"},{"issue":"s1","key":"8374_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3747\/co.23.3099","volume":"23","author":"D Abrams","year":"2016","unstructured":"Abrams D (2016) Integrating cannabis into clinical cancer care. Curr Oncol 23(s1):8\u201314","journal-title":"Curr Oncol"},{"issue":"1\u20132","key":"8374_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jep.2006.02.001","volume":"105","author":"MB Amar","year":"2006","unstructured":"Amar MB (2006) Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 105(1\u20132):1\u201325","journal-title":"J Ethnopharmacol"},{"issue":"9","key":"8374_CR24","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1093\/annonc\/mdq727","volume":"22","author":"T Brisbois","year":"2011","unstructured":"Brisbois T, De Kock I, Watanabe S, Mirhosseini M, Lamoureux D, Chasen M et al (2011) Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 22(9):2086\u20132093","journal-title":"Ann Oncol"},{"issue":"10","key":"8374_CR25","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.21873\/anticanres.13783","volume":"39","author":"R Likar","year":"2019","unstructured":"Likar R, Koestenberger M, Stultschnig M, Nahler G (2019) Concomitant treatment of malignant brain tumours with CBD\u2013a case series and review of the literature. Anticancer Res 39(10):5797\u20135801","journal-title":"Anticancer Res"},{"issue":"58","key":"8374_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/jncimonographs\/lgab008","volume":"2021","author":"SD McAllister","year":"2021","unstructured":"McAllister SD, Abood ME, Califano J, Guzm\u00e1n M (2021) Cannabinoid cancer biology and prevention. JNCI Monogr 2021(58):99\u2013106","journal-title":"JNCI Monogr"},{"issue":"1\u20133","key":"8374_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejphar.2006.11.006","volume":"556","author":"B Costa","year":"2007","unstructured":"Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M (2007) The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 556(1\u20133):75\u201383","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"8374_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R et al (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175(3):225\u2013231","journal-title":"Am J Psychiatry"},{"key":"8374_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","volume":"41","author":"IM Linares","year":"2018","unstructured":"Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimar\u00e3es FS et al (2018) Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry 41:9\u201314","journal-title":"Braz J Psychiatry"},{"issue":"3","key":"8374_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3747\/co.25.3983","volume":"25","author":"K Martell","year":"2018","unstructured":"Martell K, Fairchild A, LeGerrier B, Sinha R, Baker S, Liu H et al (2018) Rates of cannabis use in patients with cancer. Curr Oncol 25(3):219\u2013225","journal-title":"Curr Oncol"},{"issue":"8","key":"8374_CR31","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/pon.4365","volume":"26","author":"I Braun","year":"2017","unstructured":"Braun I, Meyer F, Gagne J, Nabati L, Yuppa D, Carmona M et al (2017) Experts\u2019 perspectives on the role of medical marijuana in oncology: A semistructured interview study. Psychooncology 26(8):1087\u20131092","journal-title":"Psychooncology"},{"issue":"22","key":"8374_CR32","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1002\/cncr.30879","volume":"123","author":"SA Pergam","year":"2017","unstructured":"Pergam SA, Woodfield MC, Lee CM, Cheng GS, Baker KK, Marquis SR et al (2017) Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer 123(22):4488\u20134497","journal-title":"Cancer"},{"key":"8374_CR33","doi-asserted-by":"publisher","unstructured":"Zylla DM, Jax S, Schmiechen K, Jelle K, Gilmore G (2022) A novel cannabis education clinic for patients with cancer: patient characteristics from initial visit. J Clin Oncol 40(28_suppl):298-298. https:\/\/doi.org\/10.1200\/JCO.2022.40.28_suppl.298","DOI":"10.1200\/JCO.2022.40.28_suppl.298"},{"issue":"58","key":"8374_CR34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/jncimonographs\/lgab010","volume":"2021","author":"DI Abrams","year":"2021","unstructured":"Abrams DI, Velasco G, Twelves C, Ganju RK, Bar-Sela G (2021) Cancer treatment: Preclinical & clinical. JNCI Monographs 2021(58):107\u2013113","journal-title":"JNCI Monographs"},{"issue":"18","key":"8374_CR35","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1002\/cncr.33646","volume":"127","author":"MM Cousins","year":"2021","unstructured":"Cousins MM, Jannausch ML, Coughlin LN, Jagsi R, Ilgen MA (2021) Prevalence of cannabis use among individuals with a history of cancer in the United States. Cancer 127(18):3437\u20133444","journal-title":"Cancer"},{"issue":"1","key":"8374_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1089\/can.2018.0009","volume":"3","author":"M Guzm\u00e1n","year":"2018","unstructured":"Guzm\u00e1n M (2018) Cannabis for the management of cancer symptoms: THC Version 2.0? Cannabis Cannabinoid Res 3(1):117\u20139","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"8374_CR37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1089\/can.2017.0012","volume":"2","author":"A Reiman","year":"2017","unstructured":"Reiman A, Welty M, Solomon P (2017) Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res 2(1):160\u2013166","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"8374_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/TCRM.S1132","volume":"4","author":"MA Ware","year":"2008","unstructured":"Ware MA, Daeninck P, Maida V (2008) A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag 4(1):99","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"8374_CR39","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jpain.2015.07.014","volume":"16","author":"MA Ware","year":"2015","unstructured":"Ware MA, Wang T, Shapiro S, Collet J-P, Boulanger A, Esdaile JM et al (2015) Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain 16(12):1233\u20131242","journal-title":"J Pain"},{"issue":"58","key":"8374_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/jncimonographs\/lgab012","volume":"2021","author":"IM Braun","year":"2021","unstructured":"Braun IM, Abrams DI, Blansky SE, Pergam SA (2021) Cannabis and the cancer patient. JNCI Monographs 2021(58):68\u201377","journal-title":"JNCI Monographs"},{"key":"8374_CR41","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.drugalcdep.2018.11.012","volume":"195","author":"BJ Arterberry","year":"2019","unstructured":"Arterberry BJ, Padovano HT, Foster KT, Zucker RA, Hicks BM (2019) Higher average potency across the United States is associated with progression to first cannabis use disorder symptom. Drug Alcohol Depend 195:186\u2013192","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"8374_CR42","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/0890117119899218","volume":"34","author":"DJ Kruger","year":"2020","unstructured":"Kruger DJ, Kruger JS, Collins RL (2020) Cannabis enthusiasts\u2019 knowledge of medical treatment effectiveness and increased risks from cannabis use. Am J Health Promot 34(4):436\u2013439","journal-title":"Am J Health Promot"},{"issue":"1","key":"8374_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/09687637.2020.1752150","volume":"28","author":"DJ Kruger","year":"2021","unstructured":"Kruger DJ, Kruger JS, Collins RL (2021) Frequent cannabis users demonstrate low knowledge of cannabinoid content and dosages. Drugs Educ Prev Policy 28(1):97\u2013103","journal-title":"Drugs Educ Prev Policy"},{"issue":"4","key":"8374_CR44","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1089\/can.2019.0101","volume":"5","author":"J Corroon","year":"2020","unstructured":"Corroon J, MacKay D, Dolphin W (2020) Labeling of cannabidiol products: a public health perspective. Cannabis Cannabinoid Res 5(4):274\u2013278","journal-title":"Cannabis Cannabinoid Res"},{"key":"8374_CR45","doi-asserted-by":"publisher","first-page":"108514","DOI":"10.1016\/j.yebeh.2021.108514","volume":"127","author":"OS Miller","year":"2022","unstructured":"Miller OS, Elder EJ Jr, Jones KJ, Gidal BE (2022) Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners. Epilepsy Behav 127:108514","journal-title":"Epilepsy Behav"},{"issue":"5","key":"8374_CR46","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/19390211.2020.1766634","volume":"17","author":"BJ Gurley","year":"2020","unstructured":"Gurley BJ, Murphy TP, Gul W, Walker LA, ElSohly M (2020) Content versus label claims in cannabidiol (CBD)-containing products obtained from commercial outlets in the state of Mississippi. J Diet Suppl 17(5):599\u2013607","journal-title":"J Diet Suppl"},{"key":"8374_CR47","volume-title":"The SAS system for Windows","author":"SAS Institute","year":"2011","unstructured":"Institute SAS (2011) The SAS system for Windows. SAS Institute, Cary, NC"},{"issue":"1","key":"8374_CR48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/1524839920923999","volume":"22","author":"JS Kruger","year":"2021","unstructured":"Kruger JS, Kruger D, Collins RL (2021) Knowledge and practice of harm reduction strategies among people who report frequent cannabis use. Health Promot Pract 22(1):24\u201330","journal-title":"Health Promot Pract"},{"key":"8374_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.drugalcdep.2017.02.003","volume":"175","author":"MN Newmeyer","year":"2017","unstructured":"Newmeyer MN, Swortwood MJ, Abulseoud OA, Huestis MA (2017) Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. Drug Alcohol Depend 175:67\u201376","journal-title":"Drug Alcohol Depend"},{"key":"8374_CR50","doi-asserted-by":"crossref","unstructured":"Barrus DG, Capogrossi KL, Cates SC, Gourdet CK, Peiper NC, Novak SP, ... Wiley JL (2016) Tasty THC: promises and challenges of cannabis edibles. Methods report RTI Press","DOI":"10.3768\/rtipress.2016.op.0035.1611"},{"issue":"10","key":"8374_CR51","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.addbeh.2014.05.013","volume":"39","author":"M Loflin","year":"2014","unstructured":"Loflin M, Earleywine M (2014) A new method of cannabis ingestion: the dangers of dabs? Addict Behav 39(10):1430\u20131433","journal-title":"Addict Behav"},{"issue":"4","key":"8374_CR52","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/jat\/bky104","volume":"43","author":"TR Spindle","year":"2019","unstructured":"Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R et al (2019) Acute pharmacokinetic profile of smoked and vaporized cannabis in human blood and oral fluid. J Anal Toxicol 43(4):233\u2013258","journal-title":"J Anal Toxicol"},{"issue":"1","key":"8374_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-020-05756-8","volume":"20","author":"P Hawley","year":"2020","unstructured":"Hawley P, Gobbo M, Afghari N (2020) The impact of legalization of access to recreational Cannabis on Canadian medical users with Cancer. BMC Health Serv Res 20(1):1\u201312","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"8374_CR54","first-page":"1","volume":"6","author":"RL Ashare","year":"2023","unstructured":"Ashare RL, Turay E, Worster B, Wetherill RR, Bidwell LC, Doucette A et al (2023) Social Determinants of Health Associated with How Cannabis is Obtained and Used in Patients with Cancer Receiving Care at a Cancer Treatment Center in Pennsylvania. Cannabis 6(2):1","journal-title":"Cannabis"},{"key":"8374_CR55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.drugpo.2017.01.018","volume":"43","author":"C Gourdet","year":"2017","unstructured":"Gourdet C, Giombi KC, Kosa K, Wiley J, Cates S (2017) How four US states are regulating recreational marijuana edibles. Int J Drug Policy 43:83\u201390","journal-title":"Int J Drug Policy"},{"issue":"1","key":"8374_CR56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cncr.33202","volume":"127","author":"IM Braun","year":"2021","unstructured":"Braun IM, Nayak MM, Revette A, Wright AA, Chai PR, Yusufov M et al (2021) Cancer patients\u2019 experiences with medicinal cannabis\u2013related care. Cancer 127(1):67\u201373","journal-title":"Cancer"},{"key":"8374_CR57","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/BF02600041","volume":"11","author":"NA Hanchak","year":"1996","unstructured":"Hanchak NA, Patel MB, Berlin JA, Strom BL (1996) Patient misunderstanding of dosing instructions. J Gen Intern Med 11:325\u2013328","journal-title":"J Gen Intern Med"},{"key":"8374_CR58","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11606-008-0833-4","volume":"24","author":"TC Davis","year":"2009","unstructured":"Davis TC, Federman AD, Bass PF, Jackson RH, Middlebrooks M, Parker RM et al (2009) Improving patient understanding of prescription drug label instructions. J Gen Intern Med 24:57\u201362","journal-title":"J Gen Intern Med"},{"issue":"9","key":"8374_CR59","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.sapharm.2017.12.005","volume":"14","author":"OO Shiyanbola","year":"2018","unstructured":"Shiyanbola OO, Unni E, Huang Y-M, Lanier C (2018) The association of health literacy with illness perceptions, medication beliefs, and medication adherence among individuals with type 2 diabetes. Res Social Adm Pharm 14(9):824\u2013830","journal-title":"Res Social Adm Pharm"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08374-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08374-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08374-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T04:09:56Z","timestamp":1713326996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08374-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["8374"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08374-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"2 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We confirm that we have read the Editorial Policy pages. This study was conducted with the approval from the Roswell Park Institutional Review Board, located in Buffalo, New York. This study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maciej Goniewicz received a research grant from Pfizer and serves as a member of the scientific advisory board to Johnson & Johnson. All other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}